Unknown

Dataset Information

Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.


ABSTRACT: Introduction: Plasma kallikrein is a  mediator of vascular leakage and inflammation. Activation of plasma kallikrein can induce features of diabetic macular edema (DME) in preclinical models. Human vitreous shows elevated plasma kallikrein levels in patients with DME. Because of the incomplete response of some patients to anti-VEGF agents, and the treatment burden associated with frequent dosing, there is still considerable need for VEGF-independent targeted pathways.Areas covered: This review covers the role of plasma kallikrein in the pathogenesis of DME and the therapeutic potential of plasma kallikrein inhibitors. It discusses early clinical studies of plasma kallikrein pathway modulation for DME, which have been associated with some improvement in visual acuity but with limited improv

SUBMITTER: Bhatwadekar AD 

PROVIDER: S-EPMC7265898 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature